50 different cancers findable in DNA blood test designed with AI

Researchers have used machine learning to develop a blood test that can find 50 or so types of cancer.

As published online March 30 in Annals of Oncology and covered in The Guardian, the test looks for chemical changes in DNA that’s circulating in the blood after being shed by tumors.

The multi-institution team, which included researchers from Harvard Medical School, Cleveland Clinic, Mayo Clinic and numerous others, trained its AI on data from 3,052 participants. Of these, 1,531 had cancer and 1,521 did not.

They found their system flagged and differentiated around 50 types of cancer in the correct proportion of the sample—44% of the time.

The more advanced the cancer, the better the detection. For example, the system found stage-1 cancers 18% of the time while finding stage-4 disease at a 93% clip.

“In pregnant women we look in their free-floating DNA for fetal abnormalities,” co-lead author Geoffrey Oxnard, MD, of the Dana-Farber Cancer Institute tells the Guardian. “We know this [approach] exists; the question is how do you fine-tune and perfect the art of looking for cancer in this free-floating DNA? And that is what the machine learning did.”

The study arrives just a few days after researchers presented an AI-powered blood test that can detect lung cancer with DNA analysis.

Access the full 50-cancers study here and the Guardian article below.  

Dave Pearson

Dave P. has worked in journalism, marketing and public relations for more than 30 years, frequently concentrating on hospitals, healthcare technology and Catholic communications. He has also specialized in fundraising communications, ghostwriting for CEOs of local, national and global charities, nonprofits and foundations.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.